Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Psychiatry

Standard Treatment and Management Options

At a Glance

Tardive dyskinesia treatment balances reducing involuntary movements with keeping the underlying condition stable. Options include carefully reviewing medicines, VMAT2 inhibitors such as valbenazine or deutetrabenazine, and regular AIMS monitoring.

Managing Tardive Dyskinesia (TD) is a balancing act. Your care team must weigh the need to control involuntary movements against the need to keep your underlying psychiatric or medical condition stable [1][2].

Current medical guidelines outline evidence-based treatment strategies for TD. Treatment is not a “one-size-fits-all” approach and is typically divided into adjusting your current medications and, if needed, adding specific TD-targeted treatments [1][3].

Step 1: Evaluating Your Current Medications

The first step in standard care is a review of the dopamine-receptor-blocking agent (DRBA) that caused the TD. Your doctor will consider several strategies [4][2]:

  • Dose Reduction: Lowering the dose of the causative drug may be considered if your prescriber determines it is clinically feasible [4], but it is not an automatic first-line step because it carries a risk of psychiatric relapse or hospitalization [5][6]. Reducing the dose does not always stop the movements, and any reduction should be a shared decision.
  • Switching Medications: If you must stay on an antipsychotic, your doctor may suggest switching to one with a lower “affinity” for dopamine receptors, such as clozapine or quetiapine [7][4]. Clozapine, in particular, has shown benefit in reducing TD symptoms, though it requires specialized blood monitoring [8], and any switch requires individualized psychiatric supervision.
  • A Warning on Anticholinergics: Medications like benztropine or trihexyphenidyl (often used for “shaking” or stiffness) are generally not a treatment for TD itself and can actually make TD movements worse by further upsetting the brain’s chemical balance [9][2]. Do not stop taking them on your own; instead, ask your prescriber what syndrome they are treating and whether adjusting them is appropriate.

Step 2: Targeted Treatment with VMAT2 Inhibitors

For patients with moderate-to-severe or disabling TD, the APA recommends discussing a class of medications called VMAT2 inhibitors [1][3]. These drugs work by reducing the amount of dopamine released into the brain’s movement centers, helping to calm the “excessive” signals that cause TD [10].

There are two primary FDA-approved options in this class:

Valbenazine

Valbenazine is a once-daily pill [11].

  • Efficacy: In specific clinical trials, research shows that about 40% of patients achieve at least a 50% reduction in their movement symptoms within 6 weeks of treatment [12].
  • Dosage: Usually starts at 40 mg and can be increased to 60 mg or 80 mg based on how you respond [13][14].
  • Side Effects: The most common side effect is somnolence (sleepiness or sedation), affecting about 11% of patients [15].

Deutetrabenazine

Deutetrabenazine is typically taken once or twice daily with food [16][17].

  • Efficacy: In specific clinical trials, about 34% to 67% of patients experience a 50% or greater improvement in movements over time [16][18].
  • Dosage: It is slowly increased (titrated) starting from 12 mg per day up to a maximum of 48 mg per day [19].
  • Side Effects: Common side effects include headache, sleepiness, nausea, and dry mouth [20].

What to Expect from Treatment

It is important to know that VMAT2 inhibitors are not a cure for TD; they are management tools [21].

  • Sustainability: Improvements often last as long as you take the medication, but if you stop, the TD movements usually return to their original level within a few weeks [21][22].
  • Mental Health Stability: Trials have shown that these drugs generally do not worsen underlying psychiatric symptoms or increase the risk of depression or suicidal thoughts in the TD population [12][23]. However, trial results are not an absolute guarantee; patients should be monitored for new or worsening depression, agitation, or suicidal thoughts, which require prompt contact or emergency help.
  • Additional Safety Considerations: Additional important side effects include the potential for parkinsonism (stiffness), akathisia (severe restlessness), QT prolongation, and the need for dose adjustments based on liver function or certain other medications.

Measurement-Based Care and Support

Your treatment should be guided by measurement-based care. This means your doctor should use the AIMS scale (covered on the symptoms page) at least annually, or as clinically indicated, to objectively track whether your movements are improving [24][1].

Because TD can affect your daily functioning, ask your doctor about supportive therapies. A speech-language pathologist can help with swallowing or speech issues, and regular dental care is vital if you have mouth movements that cause tooth wear or injury. If one strategy does not work or causes too many side effects, your doctor can adjust the dose or try a different medication. The goal is to reach a point where your movements are minimized while your mental health remains a priority [2].

Common questions in this guide

What are the usual treatment options for tardive dyskinesia?
Treatment usually begins with a review of the medicine that may have caused tardive dyskinesia. A clinician may consider a carefully monitored dose reduction or a switch to another medicine, and may discuss a VMAT2 inhibitor for moderate-to-severe or disabling movements.
Can changing my antipsychotic medicine stop tardive dyskinesia?
Reducing the dose or switching to a medicine such as clozapine or quetiapine may help some people, but it does not always stop the movements. Any change must be individualized and monitored because lowering psychiatric medicine can cause symptoms of the underlying condition to return.
Are valbenazine and deutetrabenazine used to treat tardive dyskinesia?
Yes. Valbenazine and deutetrabenazine are FDA-approved VMAT2 inhibitor medicines that can reduce tardive dyskinesia movements, especially when symptoms are moderate, severe, or disabling. They manage symptoms rather than cure the condition, so movements may return after treatment is stopped.
Can anticholinergic medicines make tardive dyskinesia worse?
Medicines such as benztropine and trihexyphenidyl generally do not treat tardive dyskinesia and may worsen its movements. Do not stop one on your own, because it may be treating a different problem; ask your prescriber whether its risks and benefits should be reassessed.
What side effects should I watch for with VMAT2 inhibitors?
Valbenazine may cause sleepiness or sedation, while deutetrabenazine may cause headache, sleepiness, nausea, or dry mouth. Clinicians may also monitor for stiffness, severe restlessness, heart-rhythm changes, liver-related dosing concerns, medication interactions, and new or worsening mood symptoms.
How do doctors measure whether tardive dyskinesia treatment is working?
Doctors can use the Abnormal Involuntary Movement Scale, or AIMS, to track changes in movement severity over time. The scale is generally used at least once a year or more often when clinically appropriate, together with goals for daily function and mental health stability.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on current guidelines, am I a candidate for a VMAT2 inhibitor, and what are the potential side effects for me?
  2. 2.If we consider reducing my dose of my current medication, how will we monitor for a psychiatric relapse?
  3. 3.What is my current AIMS score, and what functional goals are we aiming for to consider treatment successful?
  4. 4.Since I am currently taking an anticholinergic drug, should we discuss its risks and benefits for my specific symptoms?
  5. 5.Is switching to a medication like clozapine or quetiapine a safe option for my underlying mental health?
  6. 6.How will you monitor me for new symptoms like sedation or parkinsonism once I start a new TD treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Measurement-based Diagnosis and Treatment for Tardive Dyskinesia.

    Correll CU, Citrome L

    The Journal of clinical psychiatry 2021; (82(5)).

    PMID: 34464521
  2. 2

    Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.

    Ward KM, Citrome L

    Neurology and therapy 2018; (7(2)):233-248 doi:10.1007/s40120-018-0105-0.

    PMID: 30027457
  3. 3

    Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.

    Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S

    Journal of the neurological sciences 2018; (389()):67-75 doi:10.1016/j.jns.2018.02.010.

    PMID: 29454493
  4. 4

    Treatment Recommendations for Tardive Dyskinesia.

    Ricciardi L, Pringsheim T, Barnes TRE, et al.

    Canadian journal of psychiatry. Revue canadienne de psychiatrie 2019; (64(6)):388-399 doi:10.1177/0706743719828968.

    PMID: 30791698
  5. 5

    Tardive Dyskinesia in Older Persons Taking Antipsychotics.

    Citrome L, Isaacson SH, Larson D, Kremens D

    Neuropsychiatric disease and treatment 2021; (17()):3127-3134 doi:10.2147/NDT.S328301.

    PMID: 34703232
  6. 6

    The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia.

    Zichlin ML, Mu F, Leo S, Ayyagari R

    Clinical drug investigation 2021; (41(10)):853-863 doi:10.1007/s40261-021-01060-3.

    PMID: 34480726
  7. 7

    Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review.

    Pardis P, Remington G, Panda R, et al.

    Journal of psychopharmacology (Oxford, England) 2019; (33(10)):1187-1198 doi:10.1177/0269881119862535.

    PMID: 31347436
  8. 8

    Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.

    Mentzel TQ, van der Snoek R, Lieverse R, et al.

    The Journal of clinical psychiatry 2018; (79(6)).

    PMID: 30257080
  9. 9

    An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.

    Vanegas-Arroyave N, Caroff SN, Citrome L, et al.

    CNS drugs 2024; (38(4)):239-254 doi:10.1007/s40263-024-01078-z.

    PMID: 38502289
  10. 10

    Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects.

    Bauer M, Bamminger K, Pichler V, et al.

    Clinical pharmacology and therapeutics 2021; (109(3)):754-761 doi:10.1002/cpt.2052.

    PMID: 32966590
  11. 11

    Valbenazine for tardive dyskinesia: a systematic review and network meta-analysis.

    Kishi T, Sakuma K, Iwata N

    International clinical psychopharmacology 2023; (38(6)):369-374 doi:10.1097/YIC.0000000000000485.

    PMID: 37694845
  12. 12

    Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.

    Solmi M, Pigato G, Kane JM, Correll CU

    Drug design, development and therapy 2018; (12()):1215-1238 doi:10.2147/DDDT.S133205.

    PMID: 29795977
  13. 13

    A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.

    Marder SR, Singer C, Lindenmayer JP, et al.

    Journal of clinical psychopharmacology 2019; (39(6)):620-627 doi:10.1097/JCP.0000000000001111.

    PMID: 31688452
  14. 14

    A Model-Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia.

    Nguyen HQ, Kuan HS, Crass RL, et al.

    Journal of clinical pharmacology 2024; (64(11)):1456-1465 doi:10.1002/jcph.2498.

    PMID: 39051716
  15. 15

    Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

    Citrome L

    International journal of clinical practice 2017; (71(7)) doi:10.1111/ijcp.12964.

    PMID: 28497864
  16. 16

    Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

    Citrome L

    International journal of clinical practice 2017; (71(11)) doi:10.1111/ijcp.13030.

    PMID: 29024264
  17. 17

    Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease.

    Moondra P, Jimenez-Shahed J

    Expert review of neurotherapeutics 2024; (24(9)):849-863 doi:10.1080/14737175.2024.2376107.

    PMID: 38982802
  18. 18

    Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.

    Hauser RA, Barkay H, Fernandez HH, et al.

    Frontiers in neurology 2022; (13()):773999 doi:10.3389/fneur.2022.773999.

    PMID: 35280262
  19. 19

    Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.

    Fernandez HH, Stamler D, Davis MD, et al.

    Journal of neurology, neurosurgery, and psychiatry 2019; (90(12)):1317-1323 doi:10.1136/jnnp-2018-319918.

    PMID: 31296586
  20. 20

    Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Anderson KE, Stamler D, Davis MD, et al.

    The lancet. Psychiatry 2017; (4(8)):595-604 doi:10.1016/S2215-0366(17)30236-5.

    PMID: 28668671
  21. 21

    The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.

    Factor SA, Remington G, Comella CL, et al.

    The Journal of clinical psychiatry 2017; (78(9)):1344-1350.

    PMID: 29141124
  22. 22

    Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.

    Kane JM, Correll CU, Liang GS, et al.

    Psychopharmacology bulletin 2017; (47(3)):69-76 doi:10.64719/pb.4366.

    PMID: 28839342
  23. 23

    Acute exacerbation of major depressive disorder following valbenazine treatment for tardive dyskinesia: A case report.

    Yano F, Oda Y, Hirose Y, et al.

    PCN reports : psychiatry and clinical neurosciences 2025; (4(3)):e70204 doi:10.1002/pcn5.70204.

    PMID: 40959715
  24. 24

    How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care.

    McEvoy JP

    The Journal of clinical psychiatry 2020; (81(6)).

    PMID: 33147658

This page is for informational purposes only and does not constitute medical advice. Do not change or stop psychiatric medicines on your own; discuss medication changes and monitoring with your prescriber.

Get notified when new evidence is published on Tardive Dyskinesia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.